Research programme: vascular endothelial growth factor receptor 3 inhibitors- Bionomics/Cancer Therapeutics CRC

Drug Profile

Research programme: vascular endothelial growth factor receptor 3 inhibitors- Bionomics/Cancer Therapeutics CRC

Alternative Names: BL 011256; BNC 420; CTx 0357927; CTx-927

Latest Information Update: 21 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cancer Therapeutics CRC
  • Developer Bionomics; Cancer Therapeutics CRC
  • Class Small molecules
  • Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Malignant melanoma
  • Research Breast cancer; Solid tumours

Most Recent Events

  • 05 Mar 2014 Early research in Solid tumours in Australia (unspecified route)
  • 13 Feb 2014 Pharmacokinetics and pharmacodynamics data from a preclinical trial in Malignant melanoma released by Bionomics
  • 16 May 2013 Bionomics exercised its commercialisation option for BL 011256 with Cancer Therapeutics CRC
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top